BMO Capital Markets Cuts Integra LifeSciences (NASDAQ:IART) Price Target to $15.00

Integra LifeSciences (NASDAQ:IART) had its price objective trimmed by BMO Capital Markets from $18.00 to $15.00 in a report published on Monday morning,Benzinga reports. The firm currently has a market perform rating on the life sciences company’s stock.

Other equities research analysts also recently issued reports about the company. Weiss Ratings downgraded Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Citigroup reaffirmed a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. Wells Fargo & Company set a $15.00 target price on Integra LifeSciences in a research report on Saturday. Finally, UBS Group initiated coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $17.29.

Integra LifeSciences Stock Down 2.4%

Shares of IART opened at $13.00 on Monday. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. Integra LifeSciences has a 12-month low of $8.70 and a 12-month high of $20.49. The business’s 50 day moving average is $16.36 and its 200 day moving average is $15.28. The company has a market capitalization of $1.01 billion, a PE ratio of -144.43, a price-to-earnings-growth ratio of 0.69 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The company had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently modified their holdings of the company. Sequoia Financial Advisors LLC lifted its holdings in shares of Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 3,059 shares during the period. State of Wyoming lifted its stake in Integra LifeSciences by 26.3% during the fourth quarter. State of Wyoming now owns 19,998 shares of the life sciences company’s stock worth $248,000 after purchasing an additional 4,168 shares during the period. Public Employees Retirement System of Ohio acquired a new stake in Integra LifeSciences during the second quarter valued at approximately $82,000. Integrated Wealth Concepts LLC acquired a new stake in Integra LifeSciences in the 2nd quarter valued at $84,000. Finally, Amundi grew its position in Integra LifeSciences by 80.8% in the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after acquiring an additional 8,681 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.